Kathy Hibbs Sells 6,250 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $8.13, for a total value of $50,812.50. Following the transaction, the director directly owned 96,992 shares of the company’s stock, valued at approximately $788,544.96. The trade was a 6.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Trading Up 3.4%

Shares of NASDAQ:SOPH opened at $7.87 on Friday. SOPHiA GENETICS SA has a 1 year low of $3.10 and a 1 year high of $8.98. The firm has a market capitalization of $660.25 million, a price-to-earnings ratio of -6.84 and a beta of 0.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The business’s 50 day moving average price is $7.03 and its 200-day moving average price is $5.68.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. HC Wainwright boosted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, SOPHiA GENETICS currently has an average rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Federated Hermes Inc. lifted its position in SOPHiA GENETICS by 16.4% during the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after buying an additional 31,000 shares in the last quarter. Akre Capital Management LLC boosted its stake in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS in the 3rd quarter valued at $49,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.